- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01181934
The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects.
March 19, 2012 updated by: Janssen Pharmaceutica N.V., Belgium
A Double-Blind, Placebo-Controlled, Randomized Three-Way Crossover Study to Investigate The Effect of Nicotine on Arousal, Standard Cognitive Tasks And Social Cognition in Young and Elderly Healthy Subjects
This study in young and elderly healthy subjects will investigate the effect of nicotine on arousal, cognitive task and social cognition after acute dose administration.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a double-blind (neither physician nor subject knows the name of the assigned drug), placebo-controlled, randomized (study drug assigned by chance), three-way-crossover trial (participants may receive different interventions sequentially during the trial) in young and elderly healthy volunteers.
The three-way-crossover treatment phase will consist of three blinded treatment periods separated by a wash out period (the period allowed for the entire administered drug to be eliminated from the body) of 2 to 7 days.
The study duration for each volunteer will be approximately 8 weeks.
Each volunteer enrolled will be randomized to receive Treatment A (1mg nicotine per dosing), Treatment B (2mg nicotine per dosing) or Treatment C (placebo) during one of their treatment period.
The study drug (nicotine or placebo) will be administered three times daily on Day 1 of each treatment phase as a mouth spray, separated 2 to 3 hours from each other (i.e.
0h; and 2 to 3h; and 4 to 6h post first dosing).
Three different blocks of cognitive assessments will follow, one after each drug administration.
Safety evaluations include adverse event monitoring, vital signs and clinical laboratory tests.
Each volunteer participating will receive 3 identical study drug administrations per dosing day (2 to 3 hours from each other), resulting in an overall dose of 3 mg nicotine (Treatment A), 6 mg nicotine (Treatment B) or 0 mg nicotine (Treatment C) per dosing day.
By the end of the study, after the 3-way crossover, each volunteer will have received 9 mg nicotine via mouth spray.
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Early Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Man or woman between 18 and 30 years of age inclusive (Cohort 1 only)
- Man or woman between 60 and 75 years of age, inclusive (Cohort 2 only)
- Body mass index (BMI) between 18 and 35 kg/m2, inclusive (BMI = eight/height2)
- Women must be: postmenopausal (for at least 12 months), surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), abstinent (at the discretion of the investigator/per local regulations), or if sexually active, be practicing a highly effective method of birth control and must agree to continue to use the same method of contraception throughout the study
- Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at admission (each study period)
- Men must agree to use a condom at each sexual intercourse and to not donate sperm during the study and for 3 months after receiving the last dose of study drug. In addition, their female partners should also use an appropriate method of birth control for at least the same duration
Exclusion Criteria:
- Female volunteers who are pregnant or breastfeeding
- Clinically significant abnormal values for clinical chemistry, hematology or urinalysis at screening. It is expected that laboratory values will generally be within the normal range for the laboratory, though minor deviations, which are not considered to be of clinical significance to the investigator, are acceptable. Values of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2 fold Upper Limit of Normal will be allowed
- Clinically significant abnormal physical examination, vital signs or 12-lead ECG at screening
- History of epilepsy or fits or unexplained black-outs
- Current dangerous or aggressive behavior
- Clinically significant history of drug and/or food allergies
- Recent history (within previous 6 months) of alcohol or drug abuse
- Significant history of or current significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematological disease, bronchospastic respiratory disease, dyspnea, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, infection, or any other illness that the investigator considers clinically significant should exclude the subject (Subjects with well-controlled hypertension will be allowed to participate)
- Significant history of or current psychiatric or neurological illness
- Smoking cigarettes (or equivalent) or the use of nicotine based products, within 3 months prior to study drug administration. Current use of any medication for smoking cessation such as nicotine replacement therapy, bupropion or varenicline
- Positive urine screen for drugs of abuse at screening or admission
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 001
A643 (nicotine) 1mg oromucosal nicotine spray- three times daily during each treatment period
|
1mg oromucosal nicotine spray- three times daily during each treatment period
2mg oromucosal nicotine spray- three times daily during each treatment period
|
EXPERIMENTAL: 002
A643 (nicotine) 2mg oromucosal nicotine spray- three times daily during each treatment period
|
1mg oromucosal nicotine spray- three times daily during each treatment period
2mg oromucosal nicotine spray- three times daily during each treatment period
|
PLACEBO_COMPARATOR: 003
placebo placebo - three times daily during each treatment period
|
placebo - three times daily during each treatment period
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To investigate the effect of nicotine on measures of arousal and event related potentials, especially the P50 auditory evoked potential, as well as standard cognitive tasks and social cognition.
Time Frame: 1 hour post dose
|
1 hour post dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Nicotine exposure
Time Frame: predose and 5 min post each dosing
|
predose and 5 min post each dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Study Completion (ACTUAL)
February 1, 2011
Study Registration Dates
First Submitted
August 12, 2010
First Submitted That Met QC Criteria
August 12, 2010
First Posted (ESTIMATE)
August 13, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
March 20, 2012
Last Update Submitted That Met QC Criteria
March 19, 2012
Last Verified
March 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Neurocognitive Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Cognition Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Nicotine
Other Study ID Numbers
- CR017251
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on A643 (nicotine)
-
Janssen Pharmaceutica N.V., BelgiumAgentschap voor Innovatie door Wetenschap en TechnologieCompletedSchizophrenia | Cognition Disorders
-
RAI Services CompanyCompletedSmoking | Tobacco Use | Tobacco SmokingUnited States
-
RAI Services CompanyNot yet recruiting
-
Yale UniversityAmerican University of Beirut Medical CenterRecruitingNicotine VapingUnited States
-
University of NebraskaInstitute for Science and HealthCompleted
-
Centre for Addiction and Mental HealthOntario Ministry of Health and Long Term CareCompleted
-
University of Kansas Medical CenterPatient-Centered Outcomes Research InstituteCompletedSmoking | Pulmonary Disease, Chronic Obstructive | Tobacco Use DisorderUnited States
-
RAI Services CompanyCompletedSmoking | Tobacco UseUnited States
-
Vanderbilt University Medical CenterCompletedDown Syndrome | Mild Cognitive ImpairmentUnited States
-
Milton S. Hershey Medical CenterNot yet recruiting